SCHEMBL6009060

SCHEMBL6009060

Cc1ccc(C(NCC(F)(F)CS(=O)(=O)O)C(C)C)cc1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KEAP1 Q14145 6/20 0.37
NFE2L2 Q16236 6/20 0.37
CA1 P00915 3/20 0.34
CA2 P00918 3/20 0.34
GRIA4 P48058 1/20 0.34
ACHE P22303 2/20 0.33
BCHE P06276 1/20 0.33
STAT3 P40763 1/20 0.33
ALDH1A1 P00352 2/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
CA9 Q16790 2/20 0.32
CA7 P43166 1/20 0.32
GPR139 Q6DWJ6 1/20 0.31
CA5A P35218 1/20 0.31
AKR1C3 P42330 1/20 0.31
AKR1C2 P52895 1/20 0.31
LMNA P02545 1/20 0.31
SMN1; SMN2 Q16637 1/20 0.31
PDE2A O00408 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5503942 0.80 KEAP1 (0.36) KEAP1NFE2L2ACHESTAT3ALDH1A1
SCHEMBL6008635 0.75 GRIA4 (0.40) KEAP1NFE2L2CA1CA2GRIA4
SCHEMBL5506848 0.71 NR3C1 (0.41) ALDH1A1
SCHEMBL6009865 0.69 KCNA5 (0.42) ALDH1A1KMT2ALMNA
SCHEMBL5506849 0.69 GHSR (0.39) CA1CA2ACHEBCHEALDH1A1
SCHEMBL6009959 0.69 KEAP1 (0.36) KEAP1NFE2L2ACHESTAT3ALDH1A1
SCHEMBL17995187 0.64 KEAP1 (0.39) KEAP1NFE2L2CA1CA2ACHE
SCHEMBL6008622 0.64 CA1 (0.39) CA1CA2ALDH1A1CA9CA7
SCHEMBL5504083 0.64 KEAP1 (0.36) KEAP1NFE2L2GRIA4ACHESTAT3
SCHEMBL11041781 0.62 GRIA4 (0.50) CA1CA2GRIA4ACHESTAT3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20060183800-A1 Methods and fluorinated compositions for treating amyloid-related diseases BELLUS HEALTH (INTERNATIONAL) LIMITED (CH) 2006-08-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060183800-A1 Methods and fluorinated compositions for treating amyloid-related diseases APP, PSEN1, TTR KEAP1 1179/4885NFE2L2 2049/4885CA1 291/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.